Target intelligence / Profile preview

Sodium-dependent phosphate transport protein 3 (SLC17A2)

Target
SLC17A2
Molecular classification
Transporter, Solute carrier (SLC) family, Organic anion transporter, Sodium/phosphate symporter
01

Overview

Sodium-dependent phosphate transport protein 3 (SLC17A2) is a member of the solute carrier family 17 and functions primarily as a sodium-dependent phosphate (Na+/Pi) cotransporter and membrane potential-driven organic anion transporter[1][2][3]. SLC17A2 mediates the movement of inorganic phosphate into cells, as well as the transport of urate and various organic anions, via mechanisms dependent on sodium gradients and membrane potential[3][4]. It is widely expressed in tissues such as the kidney, liver, placenta, thyroid, lung, and brain, indicating roles in systemic phosphate and urate circulation[2]. As a polyspecific transporter, SLC17A2 may contribute to both normal renal handling of phosphate and urate and the pathogenesis of disorders such as Fanconi renotubular syndrome 2[3]. Key structural and functional features: - Categorized as a sodium/phosphate symporter in the Phosphate:Na+ Symporter (PNaS) family[4]. - Has a related paralog, SLC17A4, and is distinguished from other sodium-phosphate transporters by substrate specificity and regulation[3]. - Drugs that inhibit SLC17A2 typically act by blocking its organic anion or phosphate cotransport function[2].

Other names
NPT3Na(+)/Pi cotransporter 3sodium phosphate transporter 3sodium/phosphate cotransporter 3solute carrier family 17 member 2sodium-dependent phosphate transport protein 3
02

Mechanism of action

Inhibition of organic anion transport; blockade of sodium-dependent phosphate uptake[2]

03

Biological functions

Transmembrane transport of phosphate and organic anionsSodium-dependent cotransport of phosphateUrate transportRegulation of cellular phosphate homeostasis
04

Disease associations

Fanconi renotubular syndrome 2Other possible roles in renal phosphate handling disorders and urate circulation disorders
05

Safety considerations

Potential effects on renal phosphate and urate transportpossible implications in systemic phosphate and urate homeostasis[2][3]
06

Interacting drugs

Hydrophilic nonsteroidal anti-inflammatory drugs (NSAIDs)

3 more in the full profile.

Beyond the preview

Go deeper on Sodium-dependent phosphate transport protein 3 (SLC17A2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sodium-dependent phosphate transport protein 3 (SLC17A2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call